Enterprise Value
4.782M
Cash
18.12M
Avg Qtr Burn
-6.724M
Short % of Float
3.51%
Insider Ownership
12.31%
Institutional Own.
23.83%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MT-401 Details Acute myeloid leukemia | Phase 2 Data readout | |
MT-601 Details Non-Hodgkin lymphoma | Phase 1 Data readout | |
MT-601 (w/ chemotherapy) Details Pancreatic cancer | Phase 1 Initiation |